Evanthia Galanis, Katharine E Dooley, S Keith Anderson, Cheyne B Kurokawa, Xiomara W Carrero, Joon H Uhm, Mark J Federspiel, Alexey A Leontovich, Ileana Aderca, Kimberly B Viker, Julie E Hammack, Randolph S Marks, Steven I Robinson, Derek R Johnson, Timothy J Kaufmann, Jan C Buckner, Daniel H Lachance, Terry C Burns, Caterina Giannini, Aditya Raghunathan, Ianko D Iankov, Ian F Parney
Measles virus (MV) vaccine strains have shown significant preclinical antitumor activity against glioblastoma (GBM), the most lethal glioma histology. In this first in human trial (NCT00390299), a carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA), was administered in recurrent GBM patients either at the resection cavity (Group A), or, intratumorally on day 1, followed by a second dose administered in the resection cavity after tumor resection on day 5 (Group B). A total of 22 patients received study treatment, 9 in Group A and 13 in Group B...
January 12, 2024: Nature Communications